KVUE - Kenvue Health Total Debt to Capital

Public company logo of Kenvue Inc. (KVUE)

International conflicts are complicating raw material deliveries, triggering asset write-downs in closed regions. However, diversified supply chains for over-the-counter medicines minimize external pressure. Meanwhile, talc-related litigation and high component costs are undermining the financial stability of Kenvue Inc. (KVUE). The balance of debt and equity reflects a debt load where 0.87 represents the latest level.

KVUE: Kenvue Total Debt to Capital 02/21/2024 - 10/31/2026
Core merchandise of Kenvue Health

Total debt-to-equity measures the level of financial leverage by comparing total liabilities to the amount of shareholder equity. This metric determines the business's dependence on external borrowings and the associated risks of debt servicing. By analyzing the current debt-to-equity ratio, an investor assesses the stability of the balance sheet. For Kenvue Inc. (KVUE), moderate leverage is justified by the non-cyclical demand for health products. The stable cash flows of this defensive business minimize the risks of high debt.

Competitor analysis for Kenvue Inc.

Debt to Equity Haleon|Verona Pharma PLC - Aggregate Debt to Equity|Total Debt to Capital MENS|LGND (Ligand Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital AMRX (Amneal Pharmaceuticals)|Total Debt to Capital perrigo.com PRGO|ALVO - Debt to Equity|All Debt to Shareholders' Equity Ratio LQDA (Liquidia Corp)|Galapagos Genomics (GLPG) - Debt to Equity|Total Debt to Equity Ratio ANI Pharmaceuticals Corp|MNKD (MannKind Corporation) - Total Debt to Capital|Total Debt to Capital amphastar.com|Total Debt to Equity Ratio PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - All Debt to Shareholders' Equity Ratio|Debt to Equity Theravance TBPH|Aquestive Corp (AQST) - Debt to Capital|SCPH: Total Debt to Equity Ratio|Tectonic Therapeutic, Inc. - Aggregate Debt to Capital|TNXP: Total Debt to Capital|China SXT Pharmaceuticals, Inc. - All Debt to Shareholders' Equity Ratio|EPRX (Eupraxia Pharmaceuticals, Inc.) - Total Debt to Capital|Debt to Capital BioHarvest Sciences Inc BHST|Debt to Equity eXoZymes Inc (EXOZ)|ORMP (oramed.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Entera Bio ENTX|Total Debt to Capital MindWalk Holdings, Inc. HYFT|ABVC BioPharma Inc - Total Debt to Capital|Debt to Capital Cumberland Corp|Quantum BioPharma Ltd (QNTM) - Debt to Equity|Debt to Equity Ratio FGEN|Total Debt to Equity Ratio TELO|Debt to Equity RANI|Total Debt to Equity Ratio SNYR (Synergy CHC Corp)|Total Debt to Capital rallybio.com (RLYB)|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|pulmatrix.com (PULM) - Debt to Capital|PTHL: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio APM (Aptorum Group Limited)|LYRA: Total Debt to Capital|IBO - Total Debt to Capital Coefficient|Debt to Equity TNF Pharmaceuticals Inc.|Debt to Equity Ratio YCBD (cbdMD Corp)|Total Debt to Capital PRFX|Total Debt to Equity Ratio altamiratherapeutics.com CYTO|Lipella - Total Debt to Equity Ratio|Total Debt to Capital Coefficient OptiNose Corp (OPTN)|PIRS - Debt to Equity|PROC - Total Debt to Capital|PTPI (Petros Pharmaceuticals, Inc.) - Total Debt to Equity Ratio|QLI (Qilian International Holding Group) - Debt to Equity|Total Debt to Equity Ratio SLRN|Total Debt to Capital TFF Pharmaceuticals, Inc